AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...
AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback